Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term Study to Further Evaluate the Risk of Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

NCT04635111 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT04635111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04635111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term Study to Further Evaluate the Risk of Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Lead sponsor
Daiichi Sankyo
Phase
Observational
Overall status
Recruiting
Start date
January 7, 2021
Completion date
June 1, 2036
Enrollment
30 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hepatotoxicity, tenosynovial giant cell tumor